Business Wire

ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud

24.9.2026 15:30:00 EEST | Business Wire | Press release

Share

ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform.

Stakk acquired ParaScript for its industry-leading AI-powered document processing and recognition technology, which uses advanced machine learning to process large volumes of documents with high speed and accuracy, helping organizations detect fraud earlier, prevent losses and improve outcomes.

The combined business becomes one of the largest AI-native digital trust infrastructures serving regulated industries, with more than 300 enterprise customers and more than 110 billion digital interactions processed annually across the U.S., Europe, the Middle East and Australia. Customers include many of the world's leading financial institutions, government agencies and Fortune 500 companies.

ParaScript’s technology integrates into Stakk’s SaaS platform, Digital Persona Graph, combining AI-powered document processing and recognition capabilities with identity, behavioral and contextual data to provide a more complete view of each digital interaction. This enables organizations to better identify AI-driven digital identity fraud and make explainable decisions in milliseconds.

The combined platform can support a broader range of workflows across regulated industries and jurisdictions, while its increased scale creates a continuously expanding intelligence base of emerging fraud signals. This gives customers greater visibility into evolving threats and strengthens their ability to detect and prevent fraud as new patterns emerge.

Emiliano Giacchetti has been appointed Chief Executive Officer of Stakk IQ and ParaScript. Pending shareholder approval at the upcoming Annual General Meeting, he is expected to assume the role of Group Chief Executive Officer of Stakk Limited, giving him responsibility for the strategy, operations and financial performance of Stakk Limited and its subsidiaries.

“Stakk and ParaScript have come together around a clear and urgent global requirement: helping highly regulated organizations properly vet digital interactions, identities and documents,” said Giacchetti. “The combined group has the technology, intelligence, enterprise relationships and international reach required to address that challenge at scale. It also has a substantial contracted revenue base and a clear pathway to deliver the financial commitments made to shareholders.”

Stakk board member Arthur Lo added, “The completion of this acquisition establishes Stakk as an international digital trust platform at a time when the need for stronger AI-based fraud solutions has never been greater. As generative AI, synthetic identities, deepfakes and document manipulation continue to proliferate, this deal closes the gap needed to address one of the world’s fastest growing markets.”

About ParaScript

ParaScript develops AI-powered recognition solutions that process over 100 billion documents annually, touching nearly everyone in the U.S. and people in more than 15 countries worldwide whenever they send mail, write checks or interact with financial institutions and government agencies. Leading corporations in the U.S., Europe, Latin America and Australia rely on ParaScript to automate their document processing, improving efficiency and accuracy, while reducing costs. Visit parascript.com to learn more.

About Stakk

Stakk Limited (ASX: SKK) is a scaled, profitable and globally relevant AI-native digital trust infrastructure group focused on combating fraud. Its integrated platform enables financial institutions, governments, law-enforcement agencies, healthcare providers, insurers, telecommunications companies, and other regulated enterprises to establish trust across the complete interaction – from identity verification and document authentication through to fraud prevention, transaction authorization, and real-time contextual decisioning.

Stakk combines more than 30 years of proprietary AI-powered document intelligence with contextual Digital Personas, federated signal intelligence and pre-execution decisioning. The group serves more than 300 enterprise customers across the United States, Europe, the Middle East and Australia and processes more than 110 billion interactions annually, creating a continuously expanding intelligence asset that strengthens its ability to identify and respond to evolving AI-driven fraud threats.

For more information visit stakk.tech.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260924529627/en/

Contacts

Media Contact
Frankie Keck
frankie@williammills.com
678-781-7228

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo ® ) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 09:00:00 EEST | Press release

Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one of the largest real-world evaluations of mogamulizumab in Germany and add to the growing body of evidence supporting its use in routine clinical practice.1-3 Conducted as a company-sponsored, multicentric, non-interventional, combined retro-prospective real-world study across 18 centres throughout Germany, MINT brought together cutaneous T‑cell lymphoma (CTCL) specialists to evaluate treatment outcomes with mogamulizumab in a real-world setting, with time-to-next-treatment (TTNT) as the study’s primary endpoint.1 The study captured a broad and heterog

Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 09:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural next step for Megaport. “Portugal’s digital economy is rapidly growing, and infrastructure is at the heart of that transfor

Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 19:09:00 EEST | Press release

Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,

Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 13:30:00 EEST | Press release

As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged

Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye